FS222 mAb² (F-star Therapeutics)

N/A

Report date: 2024/06/24 11:33:23

Base Information

Drug NameFS222 mAb² (F-star Therapeutics)
Drug Alias NameFS-222
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 inhibitorsProgrammed death-ligand 1 blockersT lymphocytes stimulants +[4] 
TargetsTumor necrosis factor receptor superfamily member 9Programmed death-ligand 1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandRomania +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesF-star Beta Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInvoX Pharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm Metastasis
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A